Challenges in Management of Neonatal Lupus Erythematosus: A Comprehensive Review

Document Type : Review Article

Authors

Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

10.22038/ijn.2025.83033.2602

Abstract

Neonatal lupus erythematosus (NLE) is a rare autoimmune condition which is caused by the passage of maternal autoantibodies through the placenta to the fetus. Manifestations of NLE in different organs are reversible and some are irreversible. Given the diverse and potentially life-threatening nature of NLE, the management of this condition requires a multidisciplinary approach. Research and clinical strategies in the treatment of neonatal lupus focus on managing symptoms and improving outcomes, especially in severe cases such as congenital heart block. Prenatal Therapies including fluorinated corticosteroid, intravenous immunoglobulin, terbutaline, plasmapheresis and hydroxychloroquine were suggested. Moreover, potential postnatal Therapies may include topical corticosteroids, blood or platelets transfusion, systemic corticosteroids, pacemaker insertion and anti-TNF drugs. Research should continue to explore novel therapies and improve our understanding of the disease mechanisms, aiming to further enhance treatment strategies in the future. The aim of this review is to provide an overview of the challenges in the diagnosis and management of NLE, typically including pathophysiology, clinical presentation, and therapeutic strategies.
 

Keywords

References

  1. Vanoni F, Lava SA, Fossali EF, Cavalli R, Simonetti GD, Bianchetti MG, et al. Neonatal systemic lupus erythematosus syndrome: a comprehensive review. Clin Rev Allergy Immunol. 2017;53(3):469–476.
  2. Buyon JP, Clancy RM. Neonatal lupus: basic research and clinical perspectives. Rheum Dis Clin. 2005;31(2):299–313.
  3. Lee LA, editor. Neonatal lupus erythematosus: Clinical findings and pathogenesis. J Investig Dermatol Symp Proc. 2004;9(1):52-56.
  4. Crow MK. Pathogenesis of systemic lupus erythematosus: Risks, mechanisms and therapeutic targets. Ann Rheum Dis. 2023;82(8):999–1014.
  5. Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, et al. An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management. Cureus. 2022;14(10).
  6. Saxena A, Izmirly PM, Bomar RP, Golpanian RS, Friedman DM, Eisenberg R, et al. Factors associated with long-term cardiac dysfunction in neonatal lupus. Ann Rheum Dis. 2020;79(2):217–224.
  7. Ambrosi A, Sonesson SE, Wahren-Herlenius M. Molecular mechanisms of congenital heart block. Exp Cell Res. 2014;325(1):2–9.
  8. Shimozawa H, Kono Y, Matano M, Suzuki Y, Koike Y, Yada Y, et al. Cytokine profile in two siblings with neonatal lupus erythematosus. Pediatr Int. 2015;57(6):1211–1214.
  9. Derdulska JM, Rudnicka L, Szykut-Badaczewska A, Mehrholz D, Nowicki RJ, Barańska-Rybak W, et al. Neonatal lupus erythematosus–practical guidelines. J Perinat Med. 2021;49(5):529–538.
  10. Neiman AR, Lee LA, Weston WL, Buyon JP. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr. 2000;137(5):674–680.
  11. Silverman E, Jaeggi E. Non‐cardiac manifestations of neonatal lupus erythematosus. Scand J Immunol. 2010;72(3):223–225.
  12. Chen Z, Zhang G, Xie H. A case of neonatal lupus erythematosus. Sichuan Med J. 2006;27:435.
  13. Nasef N, Hafez M, Bark A. Neonatal lupus erythematosus. J Neonatol Clin Pediatr. 2014; 1(002):1–10.
  14. Lee LA. Neonatal lupus: clinical features and management. Paediatr Drugs. 2004;6(2):71–78.
  15. Kobayashi R, Mii S, Nakano T, Harada H, Eto H. Neonatal lupus erythematosus in Japan: A review of the literature. Autoimmun Rev. 2009;8(6):462–466.
  16. Bullock T, Simonds R, McBride J, Irfan M, Young S. Neonatal lupus erythematosus: A case report and review of the literature. J Cutan Med. 2023;7(2):649–656.
  17. Miliaresis C, Izmirly PM, Buyon JP, Phoon CK, Friedman D. Neonatal Lupus: pathogenesis and clinical approaches. Dubois' Lupus Erythematosus and Related Syndromes. 2019:486–498.
  18. Eronen M, Heikkilä P, Teramo K. Congenital complete heart block in the fetus: hemodynamic features, antenatal treatment, and outcome in six cases. Pediatr Cardiol. 2001;22(5):385–392.
  19. Akbariasbagh P, Sheikh M, Akbariasbagh N, Shariat M. Extensive aortic aneurysm associated with neonatal lupus erythematosus. Ann Pediatr Cardiol. 2016;9(2):201–202.
  20. Izmirly P, Saxena A, Buyon JP. Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus. Curr Opin Rheumatol. 2017;29(5):467–472.
  21. Klein-Gitelman MS. Neonatal lupus: What we have learned and current approaches to care. Curr Rheumatol Rep. 2016;18(9):1–6.
  22. Sun W, Yuan TM, Chen LH, Yu HM. Neonatal lupus erythematosus: three case reports and review of the Chinese literature. Clin Pediatr. 2010;49(7):627–634.
  23. Brito-Zerón P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta MA. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol. 2015;11(5):301–312.
  24. Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus: Guidelines to management, integrating clues from the bench and bedside. Nat Rev Rheumatol. 2009;5(3):139–148.
  25. Sonesson SE, Ambrosi A, Wahren‐Herlenius M. Benefits of fetal echocardiographic surveillance in pregnancies at risk of congenital heart block: Single‐center study of 212 anti‐Ro52‐positive pregnancies. ISUOG. 2019;54(1):87–95.
  26. Donofrio MT, Moon-Grady AJ, Hornberger LK, Copel JA, Sklansky MS, Abuhamad A, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation. 2014;129(21):2183–2242.
  27. Saxena A, Izmirly PM, Mendez B, Buyon JP, Friedman DM. Prevention and treatment in utero of autoimmune-associated congenital heart block. Cardiol Rev. 2014;22(6):263–267.
  28. Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: Issues in diagnosis and treatment. Am J Clin Dermatol. 2009; 10(6):365–381.
  29. Izmirly PM, Saxena A, Sahl SK, Shah U, Friedman DM, Kim MY, et al. Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system. Ann Rheum Dis. 2016; 75(6):1161–1165.
  30. Levesque K, Morel N, Maltret A, Baron G, Masseau A, Orquevaux P, et al. Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. Autoimmun Rev. 2015;14(12):1154–1160.
  31. Ciardulli A, D'Antonio F, Magro‐Malosso ER, Manzoli L, Anisman P, Saccone G, et al. Maternal steroid therapy for fetuses with second‐degree immune‐mediated congenital atrioventricular block: A systematic review and meta‐analysis. Acta Obstet Gynecol Scand. 2018;97(7):787–794.
  32. Van den Berg NW, Slieker MG, van Beynum IM, Bilardo CM, de Bruijn D, Clur SA, et al. Fluorinated steroids do not improve outcome of isolated atrioventricular block. Int J Cardiol. 2016;225:167–171.
  33. Trucco SM, Jaeggi E, Cuneo B, Moon-Grady AJ, Silverman E, Silverman N, et al. Use of intravenous gamma globulin and corticosteroids in the treatment of maternal autoantibody-mediated cardiomyopathy. J Am Coll Cardiol. 2011;57(6):715–723.
  34. Yu Y, Du L, Pan J, Zheng J, Chen A, Chen L. A 10-year retrospective study of neonatal lupus erythematous in China. Asian Pac. J Allergy Immunol. 2016;34(2).
  35. Martin TA. Congenital heart block: current thoughts on management, morphologic spectrum, and role of intervention. Cardiol Young. 2014;24(S2):41–46.
  36. Friedman DM, Llanos C, Izmirly PM, Brock B, Byron J, Copel J, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open‐label clinical trial. Arthritis and Rheumatism. 2010;62(4):1138–1146.
  37. Izmirly PM, Saxena A, Kim MY, Wang D, Sahl SK, Llanos C, et al. Maternal and fetal factors associated with mortality and morbidity in a multi–racial/ethnic registry of anti-SSA/Ro–associated cardiac neonatal lupus. Circulation. 2011; 124(18):1927–1935.
  38. Moretti D, Cimaz R, Vannucci G, Marino A, Martino M, Greco A. Cutaneous neonatal lupus: a case report and review of the literature. Int J Dermatol. 2014;53(12):1508-1512
  39. Johnson B. Overview of neonatal lupus. J Pediatr Health Care. 2014;28(4):331–341.
  40. Kaaja R, Julkunen H. Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al. Arthritis and Rheumatism. 2003;48(1):280–281.
  41. Liszewska A, Woźniacka A. Neonatal lupus erythematosus–prevention is better than cure. Adv Dermatol Allergol. 2022;39(6):1021–1026.
  42. Pullen Jr RL, Branson M. Congenital heart block in neonatal lupus erythematosus. Nurs Made Incred Easy. 2018;16(5):44–53.
  43. Rivera TL, Izmirly PM, Birnbaum BK, Byrne P, Brauth JB, Katholi M, et al. Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis. 2009;68(6):828–835.
  44. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, Khamashta MA, Kim MY, Saxena A, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody–associated cardiac manifestations of neonatal lupus. Circulation. 2012;126(1):76–82.
  45. Tunks RD, Clowse ME, Miller SG, Brancazio LR, Barker PC. Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. Am J Obstet Gynecol. 2013;208(1):64-e1.
  46. Elish D, Silverberg NB. Neonatal lupus erythematosus. Cutis. 2006 Feb;77(2):82-6.
  47. Gryka-Marton M, Szukiewicz D, Teliga-Czajkowska J, Olesinska M. An overview of neonatal lupus
    with anti-Ro characteristics. Int J Mol Sci. 2021;22(17):9281.
  48. Ambrosi A, Salomonsson S, Eliasson H, Zeffer E, Skog A, Dzikaite V, et al. Development of heart block in children of SSA/SSB-autoantibody-positive women is associated with maternal age and displays a season-of-birth pattern. Ann Rheum Dis. 2012;71(3):334-340.
  49. Epstein AE, DiMarco JP, Ellenbogen KA, Estes III NM, Freedman RA, Gettes LS, et al. 2012 ACCF/AHA/
    HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report
    of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2013;127(3):e283–e352.
  50. Limaye MA, Buyon JP, Cuneo BF, Mehta‐Lee SS. A review of fetal and neonatal consequences of maternal systemic lupus erythematosus. Prenat Diagn. 2020;40(9):1066-1076.
  51. Barenbrug L, Te Groen M, Hoentjen F, van Drongelen J, van den Reek JM, Joosten I, et al. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-α during pregnancy: A systemic review and meta-analysis. J Autoimmun. 2021;122: 102676.
  52. Türkmen Ş, Gerenli N, Sözeri B. Evaluation of Lupus Cases Related to TNF Inhibitors in Children: An Adverse Reaction of Anti-TNF Therapy. The Journal of Pediatric Academy. 2023;4(4):146–148.

 

 

Iranian Journal of Neonatology
Volume 17, Issue 1
January 2026
Pages 51-57

Files

Share

How to cite

Statistics